Audit 332207

FY End
2023-09-30
Total Expended
$238.93M
Findings
0
Programs
46
Year: 2023 Accepted: 2024-12-12
Auditor: Kpmg LLP

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.498 Provider Relief Fund and American Rescue Plan (arp) Rural Distribution $8.10M Yes 0
81.049 Office of Science Financial Assistance Program $510,415 Yes 0
93.310 Trans-Nih Research Support $234,340 Yes 0
81.086 Conservation Research and Development $185,027 Yes 0
93.855 Allergy, Immunology and Transplantation Research $184,026 Yes 0
93.121 Oral Diseases and Disorders Research $158,975 Yes 0
47.049 Mathematical and Physical Sciences $149,829 Yes 0
93.172 Human Genome Research $116,460 Yes 0
93.353 21st Century Cures Act - Beau Biden Cancer Moonshot $91,145 Yes 0
93.865 Child Health and Human Development Extramural Research $68,281 Yes 0
93.350 National Center for Advancing Translational Sciences $67,829 Yes 0
47.070 Computer and Information Science and Engineering $67,423 Yes 0
93.361 Nursing Research $64,531 Yes 0
93.867 Vision Research $61,154 Yes 0
93.989 International Research and Research Training $57,496 Yes 0
99.RD Contract $54,678 Yes 0
93.262 Occupational Safety and Health Program $54,336 Yes 0
93.853 Extramural Res Prgms in Neurosciences and Neurological Disease $48,818 Yes 0
93.397 Cancer Centers Support Grants $42,586 Yes 0
47.074 Biological Sciences $40,811 Yes 0
93.839 Blood Diseases and Resources Research $39,167 Yes 0
93.837 Heart and Vascular Diseases Research $33,126 Yes 0
93.393 Cancer Cause and Prevention Research $30,828 Yes 0
10.001 Agricultural Research Basic and Applied Research $30,000 Yes 0
93.859 Biomedical Research and Research Training $28,770 Yes 0
64.054 Research & Development $27,139 Yes 0
93.838 Lung Diseases Research $23,897 Yes 0
93.279 Drug Abuse and Addiction Research Programs $21,318 Yes 0
93.242 Mental Health Research Grants $20,742 Yes 0
93.395 Cancer Treatment Research $19,118 Yes 0
93.226 Research on Healthcare Costs, Quality and Outcomes $14,593 Yes 0
93.879 Medical Library Assistance $11,381 Yes 0
93.847 Diabetes, Endocrinology and Metabolism Research $10,585 Yes 0
93.103 Food and Drug Administration - Research $5,491 Yes 0
93.399 Cancer Control $4,964 Yes 0
93.398 Cancer Research Manpower $4,157 Yes 0
93.110 Maternal and Child Health Federal Consolidated Programs $3,369 Yes 0
93.213 Research and Training in Complementary and Alternative Medicine $1,873 Yes 0
12.300 Basic and Applied Scientific Research Dept of Defense $1,614 Yes 0
93.161 National Institute of Health Health Program for Toxic Substance and Disease Registry $1,412 Yes 0
93.286 Discovery and Applied Res for Tech Innovations $676 Yes 0
93.396 Cancer Biology Research $192 Yes 0
93.846 Arthritis, Musculoskeletal and Skin Diseases Research $2 Yes 0
12.420 Military Medical Research and Development $-1 Yes 0
93.866 Aging Research $-369 Yes 0
93.394 Cancer Detection and Diagnosis Research $-10,179 Yes 0

Contacts

Name Title Type
DPMGH9MG1X67 Valeria Leite Auditee
6176323753 Sheila Harrington Auditor
No contacts on file

Notes to SEFA

Title: Definition of Reporting Entity Accounting Policies: (1) Definition of Reporting Entity -The accompanying Supplementary Schedule of Expenditures of Federal Awards (Schedule) presents the activity of all federal awards of Dana‑Farber Cancer Institute, Inc. and Subsidiaries (the Institute). All federal awards received directly from federal agencies, as well as federal awards passed through to the Institute from other agencies, are included on the Schedule. The Schedule also denotes Assistance Listing Numbers for each award and awards passed through from the Institute to other nonfederal subrecipient organizations. (2) Basis of Presentation - The Schedule is prepared on the accrual basis of accounting. Since the Schedule presents only a selected portion of the operations of the Institute, it is not intended to, and does not present the consolidated financial position or changes in net assets of the Institute. (3) Indirect Costs - Indirect costs are charged to federal grants and contracts at federally approved predetermined rates. The predetermined rate for the year ended September 30, 2023 was 78%. Indirect costs recovered are included in reported federal expenditures. The Institute has elected to not use the 10% de minimis indirect cost rate allowed under the Uniform Guidance. De Minimis Rate Used: N Rate Explanation: Indirect costs are charged to federal grants and contracts at federally approved predetermined rates. The predetermined rate for the year ended September 30, 2023 was 78%. Indirect costs recovered are included in reported federal expenditures. The Institute has elected to not use the 10% de minimis indirect cost rate allowed under the Uniform Guidance. The accompanying Supplementary Schedule of Expenditures of Federal Awards (Schedule) presents the activity of all federal awards of Dana‑Farber Cancer Institute, Inc. and Subsidiaries (the Institute). All federal awards received directly from federal agencies, as well as federal awards passed through to the Institute from other agencies, are included on the Schedule. The Schedule also denotes Assistance Listing Numbers for each award and awards passed through from the Institute to other nonfederal subrecipient organizations.
Title: Basis of Presentation Accounting Policies: (1) Definition of Reporting Entity -The accompanying Supplementary Schedule of Expenditures of Federal Awards (Schedule) presents the activity of all federal awards of Dana‑Farber Cancer Institute, Inc. and Subsidiaries (the Institute). All federal awards received directly from federal agencies, as well as federal awards passed through to the Institute from other agencies, are included on the Schedule. The Schedule also denotes Assistance Listing Numbers for each award and awards passed through from the Institute to other nonfederal subrecipient organizations. (2) Basis of Presentation - The Schedule is prepared on the accrual basis of accounting. Since the Schedule presents only a selected portion of the operations of the Institute, it is not intended to, and does not present the consolidated financial position or changes in net assets of the Institute. (3) Indirect Costs - Indirect costs are charged to federal grants and contracts at federally approved predetermined rates. The predetermined rate for the year ended September 30, 2023 was 78%. Indirect costs recovered are included in reported federal expenditures. The Institute has elected to not use the 10% de minimis indirect cost rate allowed under the Uniform Guidance. De Minimis Rate Used: N Rate Explanation: Indirect costs are charged to federal grants and contracts at federally approved predetermined rates. The predetermined rate for the year ended September 30, 2023 was 78%. Indirect costs recovered are included in reported federal expenditures. The Institute has elected to not use the 10% de minimis indirect cost rate allowed under the Uniform Guidance. The Schedule is prepared on the accrual basis of accounting. Since the Schedule presents only a selected portion of the operations of the Institute, it is not intended to, and does not present the consolidated financial position or changes in net assets of the Institute.
Title: Indirect Costs Accounting Policies: (1) Definition of Reporting Entity -The accompanying Supplementary Schedule of Expenditures of Federal Awards (Schedule) presents the activity of all federal awards of Dana‑Farber Cancer Institute, Inc. and Subsidiaries (the Institute). All federal awards received directly from federal agencies, as well as federal awards passed through to the Institute from other agencies, are included on the Schedule. The Schedule also denotes Assistance Listing Numbers for each award and awards passed through from the Institute to other nonfederal subrecipient organizations. (2) Basis of Presentation - The Schedule is prepared on the accrual basis of accounting. Since the Schedule presents only a selected portion of the operations of the Institute, it is not intended to, and does not present the consolidated financial position or changes in net assets of the Institute. (3) Indirect Costs - Indirect costs are charged to federal grants and contracts at federally approved predetermined rates. The predetermined rate for the year ended September 30, 2023 was 78%. Indirect costs recovered are included in reported federal expenditures. The Institute has elected to not use the 10% de minimis indirect cost rate allowed under the Uniform Guidance. De Minimis Rate Used: N Rate Explanation: Indirect costs are charged to federal grants and contracts at federally approved predetermined rates. The predetermined rate for the year ended September 30, 2023 was 78%. Indirect costs recovered are included in reported federal expenditures. The Institute has elected to not use the 10% de minimis indirect cost rate allowed under the Uniform Guidance. Indirect costs are charged to federal grants and contracts at federally approved predetermined rates. The predetermined rate for the year ended September 30, 2023 was 78%. Indirect costs recovered are included in reported federal expenditures. The Institute has elected to not use the 10% de minimis indirect cost rate allowed under the Uniform Guidance.